Most importantly, we show that an increase in cell numbers after the end of endocrine treatment is of highly significant clinical relevance but that a (re-)uptake of therapy can lead to re-decreasing CETC and to potentially minimize the risk of developing metastases.
← all excerpts
The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients.
1
—
—